(Total Views: 589)
Posted On: 04/09/2025 2:30:08 PM
Post# of 154630
Conclusions...PF and OS..maxes out at 12.1 mos. on Sacituzumab...Leronlimab @ 36 plus months is the obvious winner...I am thinking Jack,...the giant killer.
So Ohm's assessment of approximately 350 patients would be more than sufficient for best efficacy in the lineup of MABS....thus far.
So Ohm's assessment of approximately 350 patients would be more than sufficient for best efficacy in the lineup of MABS....thus far.
(6)
(0)
